Role of the Wnt Pathway in Thyroid Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2012 May 31

PMID 22645520

Citations 63

Authors

Ana Sastre-Perona

Pilar Santisteban

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of Wnt signaling is involved in the development of several epithelial tumors. Wnt signaling includes two major types of pathways: (i) the canonical or Wnt/β-catenin pathway; and (ii) the non-canonical pathways, which do not involve β-catenin stabilization. Among these pathways, the Wnt/β-catenin pathway has received most attention during the past years for its critical role in cancer. A number of publications emphasize the role of the Wnt/β-catenin pathway in thyroid cancer. This pathway plays a crucial role in development and epithelial renewal, and components such as β-catenin and Axin are often mutated in thyroid cancer. Although it is accepted that altered Wnt signaling is a late event in thyroid cell transformation that affects anaplastic thyroid tumors, recent data suggest that it is also altered in papillary thyroid carcinoma (PTC) with RET/PTC mutations. Therefore, the purpose of this review is to summarize the main relevant data of Wnt signaling in thyroid cancer, with special emphasis on the Wnt/β-catenin pathway.

Citing Articles

Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.

Hartmann H, Loberg M, Xu G, Schwarzkopf A, Chen S, Phifer C Endocrinology. 2025; 166(3).

PMID: 39951495 PMC: 11843548. DOI: 10.1210/endocr/bqaf030.

Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review.

Voinea I, Petrova E, Dumitru N, Cocolos A, Ioachim D, Goldstein A J Clin Med. 2024; 13(23).

PMID: 39685621 PMC: 11641973. DOI: 10.3390/jcm13237161.

Systemic treatments for radioiodine-refractory thyroid cancers.

Chen P, Yao Y, Tan H, Li J Front Endocrinol (Lausanne). 2024; 15:1346476.

PMID: 39473507 PMC: 11518755. DOI: 10.3389/fendo.2024.1346476.

Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated G in Human Cancer.

Dwyer M, Aumiller J, Wedegaertner P Mol Pharmacol. 2024; 106(5):198-215.

PMID: 39187387 PMC: 11493338. DOI: 10.1124/molpharm.124.000743.

Exploring the Therapeutic Potential of Extracellular Vesicles Derived from Human Immature Dental Pulp Cells on Papillary Thyroid Cancer.

Teixeira M, Alievi A, da Costa V, Kerkis I, Araldi R Int J Mol Sci. 2024; 25(15).

PMID: 39125748 PMC: 11311836. DOI: 10.3390/ijms25158178.

References

Hulsken J, Birchmeier W, Behrens J . E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 1994; 127(6 Pt 2):2061-9. PMC: 2120290. DOI: 10.1083/jcb.127.6.2061. View

Kroll T, Sarraf P, Pecciarini L, Chen C, Mueller E, Spiegelman B . PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483):1357-60. DOI: 10.1126/science.289.5483.1357. View

Cetta F, Chiappetta G, Melillo R, Petracci M, Montalto G, Santoro M . The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J Clin Endocrinol Metab. 1998; 83(3):1003-6. DOI: 10.1210/jcem.83.3.4614. View

Castellone M, De Falco V, Magendra Rao D, Bellelli R, Muthu M, Basolo F . The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 2009; 69(5):1867-76. PMC: 2746012. DOI: 10.1158/0008-5472.CAN-08-1982. View

Rubinfeld B, Albert I, Porfiri E, Fiol C, MUNEMITSU S, Polakis P . Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 1996; 272(5264):1023-6. DOI: 10.1126/science.272.5264.1023. View

De Felice M, Di Lauro R . Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev. 2004; 25(5):722-46. DOI: 10.1210/er.2003-0028. View

Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M . The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009; 69(21):8317-25. DOI: 10.1158/0008-5472.CAN-09-1248. View

Garcia-Rostan G, Camp R, Herrero A, Carcangiu M, Rimm D, Tallini G . Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001; 158(3):987-96. PMC: 1850336. DOI: 10.1016/s0002-9440(10)64045-x. View

Polakis P . The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007; 17(1):45-51. DOI: 10.1016/j.gde.2006.12.007. View

10.

Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y . Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid. 2005; 14(12):1020-9. DOI: 10.1089/thy.2004.14.1020. View

11.

Kim W, Lewis C, McCall K, Malgor R, Kohn A, Moon R . Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol. 2007; 193(1):93-106. DOI: 10.1677/JOE-06-0025. View

12.

Rezk S, Brynes R, Nelson V, Thein M, Patwardhan N, Fischer A . beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol. 2005; 15(4):329-37. DOI: 10.1385/ep:15:4:329. View

13.

Lepourcelet M, Chen Y, France D, Wang H, Crews P, Petersen F . Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102. DOI: 10.1016/s1535-6108(03)00334-9. View

14.

Wada H, Okamoto H . Roles of planar cell polarity pathway genes for neural migration and differentiation. Dev Growth Differ. 2009; 51(3):233-40. DOI: 10.1111/j.1440-169X.2009.01092.x. View

15.

Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V . Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010; 70(21):8874-85. DOI: 10.1158/0008-5472.CAN-10-1994. View

16.

Rao A, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J . Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2005; 91(1):159-68. DOI: 10.1210/jc.2005-1381. View

17.

Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M . Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol. 1998; 185(3):267-72. DOI: 10.1002/(SICI)1096-9896(199807)185:3<267::AID-PATH113>3.0.CO;2-C. View

18.

Meirmanov S, Nakashima M, Kondo H, Matsufuji R, Takamura N, Ishigaki K . Correlation of cytoplasmic beta-catenin and cyclin D1 overexpression during thyroid carcinogenesis around Semipalatinsk nuclear test site. Thyroid. 2003; 13(6):537-45. DOI: 10.1089/105072503322238791. View

19.

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

20.

Strumane K, Berx G, VAN Roy F . Cadherins in cancer. Handb Exp Pharmacol. 2010; (165):69-103. DOI: 10.1007/978-3-540-68170-0_4. View